Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that pMMR status confers therapeutic sensitivity to Carboplatin, Durvalumab, Olaparib, Paclitaxel in patients with Endometrial Carcinoma.
The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
This statement is based on a regulatory approval from the European Medicines Agency:
IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).